SRR8518307
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.350
- PANCREAS_BETA_CELLS+0.280
- SPERMATOGENESIS+0.180
- WNT_BETA_CATENIN_SIGNALING+0.120
- MYC_TARGETS_V1+0.080
- E2F_TARGETS+0.050
- DNA_REPAIR+0.040
- G2M_CHECKPOINT+0.040
- HEDGEHOG_SIGNALING+0.040
- APICAL_SURFACE+0.030
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.560
- INTERFERON_GAMMA_RESPONSE-0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- IL6_JAK_STAT3_SIGNALING-0.450
- ALLOGRAFT_REJECTION-0.400
- INFLAMMATORY_RESPONSE-0.390
- COMPLEMENT-0.380
- COAGULATION-0.340
- IL2_STAT5_SIGNALING-0.320
- UV_RESPONSE_DN-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208946 | — | — | 0.919 |
| 2 | TCGA-QK-A8Z7-01A-11R-A39I-07 | — | — | 0.903 |
| 3 | BS_QWNBZ9RJ | Embryonal tumors | — | 0.901 |
| 4 | SRR8518365 | — | E | 0.899 |
| 5 | TCGA-56-A4BX-01A-11R-A24H-07 | — | cohortSQ2 | 0.897 |
| 6 | TCGA-46-6026-01A-11R-1820-07 | — | cohortSQ1 | 0.893 |
| 7 | MDT-AP-0511 | Med | Medulloblastoma | 0.887 |
| 8 | SRR8518343 | — | E | 0.885 |
| 9 | TCGA-3C-AAAU-01A-11R-A41B-07 | — | B | 0.882 |
| 10 | 2e15a781-21c1-421b-9e92-6d2d414e0d14 | — | — | 0.878 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.350 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.080 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.050 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.040 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.040 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.040 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.030 | Inavolisib | — uncovered |